Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study
Sponsor: Mirati Therapeutics Inc.
Summary
A Study of Sitravatinib Alone or in Combination with Other Anticancer Therapies in Advanced or Metastatic Malignancies
Official title: A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
49
Start Date
2021-06-29
Completion Date
2025-09-25
Last Updated
2026-08-04
Healthy Volunteers
No
Interventions
Sitravatinib
Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
Nivolumab
Nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Pembrolizumab
Pembrolizumab is a programmed death receptor-1 (PD-1) blocking antibody
Enfortumab Vedotin-Ejfv
Enfortumab is a Nectin-4 directed antibody-drug conjugate (ADC) comprised of a monoclonal antibody conjugated to the small molecule microtubule disrupting agent, monomethyl auristatin E (MMAE)
Ipilimumab
Ipilimumab is a CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) blocking antibody
Locations (13)
Rocky Mountain Cancer Centers - Littleton
Littleton, Colorado, United States
Local Institution - 516-014-029
Goshen, Indiana, United States
Local Institution - 516-014-002
Boston, Massachusetts, United States
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
Local Institution - 516-014-005
Minneapolis, Minnesota, United States
Urology Cancer Center and GU Research Network
Omaha, Nebraska, United States
Local Institution - 516-014-011
Albany, New York, United States
Memorial Sloan Kettering Cancer Center - Arnold and Marie Schwartz Cancer Research Building
New York, New York, United States
Local Institution - 516-014-004
Columbus, Ohio, United States
Local Institution - 516-014-001
Austin, Texas, United States
USOR - Texas Oncology Northeast Texas - Denison
Denison, Texas, United States
Local Institution - 516-014-013
Houston, Texas, United States
NEXT Virginia
Fairfax, Virginia, United States